Status:
COMPLETED
Treatment of Alcohol Withdrawal in Hospital Patients
Lead Sponsor:
Virginia Commonwealth University
Collaborating Sponsors:
National Institute on Alcohol Abuse and Alcoholism (NIAAA)
Conditions:
Alcohol Withdrawal Syndrome
Eligibility:
All Genders
21-75 years
Phase:
PHASE4
Brief Summary
The purpose of this study is to test how tolerable and effective lorazepam is when used to treat alcohol withdrawal in hospital patients at risk for alcohol withdrawal.
Detailed Description
Studies show that symptom-triggered dosing is best for treatment of alcohol withdrawal in patients on chemical dependence units without other illness. On general medical hospital wards, withdrawal may...
Eligibility Criteria
Inclusion
- Alcohol dependence (based on criteria from the Diagnostic and Statistical Manual of Mental Disorders, 4th Edition)
- Daily alcohol use for at least seven consecutive days with the last use no more than 72 hours prior to enrollment
- Patients on the General Internal Medicine service
Exclusion
- Unable to give informed consent
- Chronically maintained on prescription sedative-hypnotics
Key Trial Info
Start Date :
April 1 2001
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
May 1 2003
Estimated Enrollment :
183 Patients enrolled
Trial Details
Trial ID
NCT00249366
Start Date
April 1 2001
End Date
May 1 2003
Last Update
April 11 2016
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Virginia Commonwealth University Medical Center
Richmond, Virginia, United States, 23219